Frazier Life Sciences Management, L.P. Chinook Therapeutics, Inc. Transaction History

Frazier Life Sciences Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 03, 2023	BUY	$18.63 - $27.35 $1.49 Million - $2.19 Million	80,000 Added 1.88%	4,345,559 $114 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $11.7 Million - $15.7 Million	670,533 Added 18.65%	4,265,559 $83.9 Million
Q2 2022 Aug 10, 2022	BUY	$12.59 - $18.8 $11.1 Million - $16.6 Million	882,985 Added 32.56%	3,595,026 $62.9 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $32.6 Million - $45.3 Million	2,712,041 New	2,712,041 $44.4 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.